Wednesday, February 10, 2021   News fundraising

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million...

fundraising

Wednesday, February 10, 2021

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (¥110 million) Series A financing round led by Hillhouse Venture Capital with participation from CCB Healthcare Growth Fund, Boyi Capital, and Longman Capital to support advancement of its lead ph